INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

EWTXEdgewise Therapeutics, Inc.

CIK 0001710072

EDGAR filingsOpen in network
Disclosed transactions41
Buys / sells0 / 13
Max Insider Score42
Connections6with evidence

EWTX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
17
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
5,781 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Derakhshan BehradChief Business Officer · Aug 14, 2026
  • ← Insider ofevidence
    Nofi MichaelChief Financial Officer · Aug 14, 2026
  • ← Insider ofevidence
    Edris BadreddinDirector · Jan 23, 2026
13
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M
—
5,781 sh
Aug 12, 2026
Aug 14, 2026
traded Aug 12, 2026
+2d
SEC FORM 4

Evidence

13
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
7,031 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

29
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$141K
3,238 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

29
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$99K
2,273 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

22
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$17K
390 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

13
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
7,031 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

5
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
32.5K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

5
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
65.0K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

17
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
5,781 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

17
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
7,500 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

33
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$95K
2,171 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

26
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$14K
304 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

26
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$6,666
150 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

33
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$108K
2,475 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

21
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
5,781 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

21
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
7,500 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

9
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
50.0K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

9
DB
Derakhshan BehradChief Business Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
100.0K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

9
NM
Nofi MichaelChief Financial Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
24.4K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

9
NM
Nofi MichaelChief Financial Officer
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
48.8K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

19
MN
Martin Christopher NathanDirector
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
16.4K sh
Jun 5, 2026Jun 16, 2026
traded Jun 5, 2026
+11dSEC FORM 4

Evidence

26
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.96M
66.5K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

15
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$403K
13.7K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

15
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$507K
17.2K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

12
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$224K
7,605 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

15
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$308K
10.5K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

0
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
10.5K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

0
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
66.5K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

0
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,605 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

0
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
17.2K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

0
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
13.7K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

11
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$5,339
13.7K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

11
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$11K
17.2K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

7
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$20K
10.5K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

14
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$128K
66.5K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

3
EB
Edris BadreddinDirector
EWTXEdgewise Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$5,400
7,605 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

15
MN
Martin Christopher NathanDirector
EWTXEdgewise Therapeutics, Inc.
Grant or award
A—
45.1K sh
Nov 19, 2025Nov 24, 2025
traded Nov 19, 2025
+5dSEC FORM 4

Evidence

13
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M—
100.0K sh
Nov 12, 2025Nov 13, 2025
traded Nov 12, 2025
+1dSEC FORM 4

Evidence

42
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Open-market sale
SELL$2.11M
100.0K sh
Nov 12, 2025Nov 13, 2025
traded Nov 12, 2025
+1dSEC FORM 4

Evidence

21
RJ
Russell Alan JDirector, Chief Scientific Officer
EWTXEdgewise Therapeutics, Inc.
Option exercise
M$18K
100.0K sh
Nov 12, 2025Nov 13, 2025
traded Nov 12, 2025
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Martin Christopher NathanDirector · Nov 24, 2025
  • ← Insider ofevidence
    Russell Alan JDirector, Chief Scientific Officer · Nov 13, 2025